SPINOCEREBELLAR ATAXIA
Clinical trials for SPINOCEREBELLAR ATAXIA explained in plain language.
Never miss a new study
Get alerted when new SPINOCEREBELLAR ATAXIA trials appear
Sign up with your email to follow new studies for SPINOCEREBELLAR ATAXIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for SCA patients: expanded access to investigational drug troriluzole
Disease control AVAILABLEThis expanded access program offers the investigational drug troriluzole to people with spinocerebellar ataxia (SCA), a rare brain disorder that affects movement and coordination. Participants take a daily pill. The goal is to provide access to the drug while it is still being st…
Matched conditions: SPINOCEREBELLAR ATAXIA
Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New study tracks rare disease SCA7 to uncover clues for future treatments
Knowledge-focused Recruiting nowThis study follows 25 people with spinocerebellar ataxia type 7 (SCA7) for up to 5 years to learn how the disease changes vision, coordination, and thinking. Participants will have yearly eye exams, brain scans, and neurological tests. No treatment is given; the goal is to gather…
Matched conditions: SPINOCEREBELLAR ATAXIA
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New study sheds light on vision loss in rare genetic brain disorders
Knowledge-focused Recruiting nowThis study looks at how spinocerebellar ataxia (SCA) affects the eyes and vision. Researchers will examine 60 adults with SCA types 1, 2, 3, or 27B, including those with early symptoms and those who are not yet symptomatic. The goal is to measure vision changes and eye damage usi…
Matched conditions: SPINOCEREBELLAR ATAXIA
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC